Posts by Peter W. PENG

Breast cancer surgery is undergoing a profound transformation, shifting from “maximum tolerable surgery” toward “minimum effective treatment.” How to precisely “do less” while maintaining oncologic efficacy, and how to redefine the role of surgery throughout the disease course, have become major topics of clinical discussion. Recently, at the 2026 Lingnan Breast Cancer Academic Forum, Oncology Frontier interviewed Prof. Liang Huang of Fudan University Shanghai Cancer Center. Drawing on his extensive clinical experience, Prof. Huang shared his insights into individualized surgical decision-making, the evidence supporting axillary de-escalation strategies, and the transformation of surgeons into “whole-course disease managers,” offering practical perspectives on balancing established principles with innovation in breast cancer surgery in the era of precision medicine.

Recently, the China Association of Chinese Medicine (CACM) Group Standard, Integrated Evaluation of Evidence on the Efficacy of Traditional Chinese Medicine was officially released in Beijing. As the world’s first guiding standard for the integrated evaluation of evidence on the efficacy of traditional Chinese medicine (TCM), the standard was jointly developed under the leadership of Researcher Xiao Xiaohe, Professor Wang Jiabo, Academician Tian Jinzhou, Academician Chen Xiangmei, and Professor Dai Aiguo, with the participation of more than 60 leading experts from 13 universities, research institutes, medical institutions, and pharmaceutical companies across China, including the Chinese PLA General Hospital, Capital Medical University, Beijing University of Chinese Medicine, and Hunan University of Chinese Medicine.

"White clouds drift above the Chilechuan Plain, while the songs of Qingcheng echo like poetry." Against this vibrant midsummer backdrop, the 2026 Chinese Clinical Oncology Annual Advances Conference (BOC) & Best of CSCO 2026 China will be held in Hohhot, Inner Mongolia, from July 3–4, 2026.

As survival continues to improve for patients with breast cancer, postoperative quality of life (QoL) has become an increasingly important factor in surgical decision-making. Breast reconstruction is an integral component of comprehensive breast cancer care, and the choice of reconstructive technique has a profound impact on long-term functional recovery and psychosocial well-being.

Perioperative chemotherapy remains a cornerstone of treatment for patients with high-risk HR-positive/HER2-negative early breast cancer. Among the commonly used regimens, dose-dense anthracycline-taxane chemotherapy has long been considered a standard option. However, important clinical questions remain regarding the optimal timing of chemotherapy, patient selection, regimen composition, and treatment intensity.